WO2004048352A3 - Inhibiteur de la dpp-iv - Google Patents

Inhibiteur de la dpp-iv Download PDF

Info

Publication number
WO2004048352A3
WO2004048352A3 PCT/JP2003/015061 JP0315061W WO2004048352A3 WO 2004048352 A3 WO2004048352 A3 WO 2004048352A3 JP 0315061 W JP0315061 W JP 0315061W WO 2004048352 A3 WO2004048352 A3 WO 2004048352A3
Authority
WO
WIPO (PCT)
Prior art keywords
dpp
cyanopyrrolidines
analogues
inhibitors
formula
Prior art date
Application number
PCT/JP2003/015061
Other languages
English (en)
Other versions
WO2004048352A2 (fr
Inventor
Ichiro Shima
Toshio Kurosaki
Original Assignee
Fujisawa Pharmaceutical Co
Ichiro Shima
Toshio Kurosaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co, Ichiro Shima, Toshio Kurosaki filed Critical Fujisawa Pharmaceutical Co
Priority to AU2003283832A priority Critical patent/AU2003283832A1/en
Publication of WO2004048352A2 publication Critical patent/WO2004048352A2/fr
Publication of WO2004048352A3 publication Critical patent/WO2004048352A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L'invention porte sur un composé (ou ses sels pharmacocompatibles) de formule (I) dans laquelle: X est CH2, O ou S; R2 est hydrogène, etc, et R1 est un fragment de formule (II) dans laquelle: R3 est alkyle inférieur, etc; et m est un entier de 1 à 3. Le composé de formule (I), qui inhibe l'activité de la DPP-IV s'avèrent utiles pour le traitement d'états médiés par la DPP-IV, tels que le diabète non insulino-dépendant.
PCT/JP2003/015061 2002-11-27 2003-11-26 Inhibiteur de la dpp-iv WO2004048352A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003283832A AU2003283832A1 (en) 2002-11-27 2003-11-26 2-cyanopyrrolidines and their analogues as dpp-iv inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002-952946 2002-11-27
AU2002952946A AU2002952946A0 (en) 2002-11-27 2002-11-27 Dpp-iv inhibitor

Publications (2)

Publication Number Publication Date
WO2004048352A2 WO2004048352A2 (fr) 2004-06-10
WO2004048352A3 true WO2004048352A3 (fr) 2004-07-08

Family

ID=29741559

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/015061 WO2004048352A2 (fr) 2002-11-27 2003-11-26 Inhibiteur de la dpp-iv

Country Status (2)

Country Link
AU (1) AU2002952946A0 (fr)
WO (1) WO2004048352A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842707B2 (en) 2004-07-23 2010-11-30 Nuada, Llc Peptidase inhibitors
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
JP2009533393A (ja) 2006-04-12 2009-09-17 プロビオドルグ エージー 酵素阻害薬
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2142514B1 (fr) 2007-04-18 2014-12-24 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
KR20200118243A (ko) * 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
JP6307989B2 (ja) * 2014-04-02 2018-04-11 住友化学株式会社 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419683A1 (fr) * 1989-04-13 1991-04-03 Japan Tobacco Inc. Nouveaux derives aminoacides possedant une activite d'inhibiteur de la prolylendopeptidase
WO2001096295A2 (fr) * 2000-06-13 2001-12-20 Novartis Ag Composes organiques
WO2002076450A1 (fr) * 2001-03-27 2002-10-03 Merck & Co., Inc. Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete
WO2002083109A1 (fr) * 2001-04-11 2002-10-24 Ferring Bv Traitement du diabete de type 2 a l'aide d'inhibiteurs de dipeptidylpeptidase iv

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419683A1 (fr) * 1989-04-13 1991-04-03 Japan Tobacco Inc. Nouveaux derives aminoacides possedant une activite d'inhibiteur de la prolylendopeptidase
WO2001096295A2 (fr) * 2000-06-13 2001-12-20 Novartis Ag Composes organiques
WO2002076450A1 (fr) * 2001-03-27 2002-10-03 Merck & Co., Inc. Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete
WO2002083109A1 (fr) * 2001-04-11 2002-10-24 Ferring Bv Traitement du diabete de type 2 a l'aide d'inhibiteurs de dipeptidylpeptidase iv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NOVARTIS A G: "NOVEL N-SUBSTITUTED-2-CYANOPYRROLIDINES AS POTENT INHIBITORS OF DIPEPTIDYL PEPTIDASE IV IN THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 10, no. 12, December 2000 (2000-12-01), pages 1937 - 1942, XP001019155, ISSN: 1354-3776 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842707B2 (en) 2004-07-23 2010-11-30 Nuada, Llc Peptidase inhibitors
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors

Also Published As

Publication number Publication date
WO2004048352A2 (fr) 2004-06-10
AU2002952946A0 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
WO2004048352A3 (fr) Inhibiteur de la dpp-iv
WO2005042533A3 (fr) Compose 2-cyanopyrrolidinecarboxamide
CA2318349A1 (fr) Oestrone sulfamate inhibant l'oestrone sulfatase, compositions pharmaceutiques associees et methodes d'utilisation
IL157773A0 (en) 2-amino-propanol derivatives
AP2002002637A0 (en) Novel piperazine
WO2004058679A3 (fr) Ligands d'adenine nucleotide translocase (ant) et compositions et methodes associees
DE69831868D1 (en) Antithrombosemittel
EP1019045A4 (fr) Agents antithrombotiques
MXPA03011981A (es) 3-fluoruro-pirrolidinas como agentes antidiabeticos.
CA2328780A1 (fr) Dihydropyrimidines
DE602005013931D1 (fr)
GB0019359D0 (en) Novel guanidines
MY140680A (en) Hepatitis c virus inhibitors
IL148498A0 (en) Quinazoline derivatives
RS101304A (sr) Indolni, azaindolni i srodni heterociklični 4-alkenil piperidinski amidi
HK1051500A1 (en) Cell adhesion inhibitors
HU9301155D0 (en) Methods for producing steroide derivatives and for their application in medical treatment
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
IS7482A (is) Fjölhringa efnasambönd sem sterk alfa2-adrenóviðtakamótlyf
ES8305325A1 (es) "procedimiento para preparar derivados de 2-oxoazetidina".
DE60114640D1 (en) Antithrombosemittel
EP1550651A4 (fr) Derive glycerol
MXPA04007643A (es) Inhibidores de la adhesion celular mediada por integrina alb2.
WO2004058683A3 (fr) Ligands d'adenine nucleotide translocase (ant) et compositions et methodes associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP